Treatment response of cystic echinococcosis to benzimidazoles: a systematic review

Stojkovic, Marija; Zwahlen, Marcel; Teggi, Antonella; Vutova, Kamenna; Cretu, Carmen M; Virdone, Roberto; Nicolaidou, Polyxeni; Cobanoglu, Nazan; Junghanss, Thomas (2009). Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS neglected tropical diseases, 3(9), e524. San Francisco, Calif.: Public Library of Science 10.1371/journal.pntd.0000524

[img]
Preview
Text
Stojkovic PLoSNeglTropDis 2009.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (501kB) | Preview

Over the past 30 years, benzimidazoles have increasingly been used to treat cystic echinococcosis (CE). The efficacy of benzimidazoles, however, remains unclear. We systematically searched MEDLINE, EMBASE, SIGLE, and CCTR to identify studies on benzimidazole treatment outcome. A large heterogeneity of methods in 23 reports precluded a meta-analysis of published results. Specialist centres were contacted to provide individual patient data. We conducted survival analyses for cyst response defined as inactive (CE4 or CE5 by the ultrasound-based World Health Organisation [WHO] classification scheme) or as disappeared. We collected data from 711 treated patients with 1,308 cysts from six centres (five countries). Analysis was restricted to 1,159 liver and peritoneal cysts. Overall, 1-2 y after initiation of benzimidazole treatment 50%-75% of active C1 cysts were classified as inactive/disappeared compared to 30%-55% of CE2 and CE3 cysts. Further in analyzing the rate of inactivation/disappearance with regard to cyst size, 50%-60% of cysts <6 cm responded to treatment after 1-2 y compared to 25%-50% of cysts >6 cm. However, 25% of cysts reverted to active status within 1.5 to 2 y after having initially responded and multiple relapses were observed; after the second and third treatment 60% of cysts relapsed within 2 y. We estimated that 2 y after treatment initiation 40% of cysts are still active or become active again. The overall efficacy of benzimidazoles has been overstated in the past. There is an urgent need for a pragmatic randomised controlled trial that compares standardized benzimidazole therapy on responsive cyst stages with the other treatment modalities.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Zwahlen, Marcel

ISSN:

1935-2727

Publisher:

Public Library of Science

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:10

Last Modified:

28 Nov 2020 02:22

Publisher DOI:

10.1371/journal.pntd.0000524

Web of Science ID:

000270818900020

BORIS DOI:

10.7892/boris.30650

URI:

https://boris.unibe.ch/id/eprint/30650 (FactScience: 194904)

Actions (login required)

Edit item Edit item
Provide Feedback